<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Craniopharyngioma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Craniopharyngioma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Craniopharyngioma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Griffith R Harsh, IV, MD, MBA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence D Recht, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen J Marcus, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Y Wen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amar Gajjar, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen A Shih, MD, MS, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 09, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Craniopharyngiomas are rare solid or mixed solid and cystic tumors that arise from remnants of Rathke's pouch along a line from the nasopharynx to the diencephalon [<a href="#rid1">1</a>]. Historically, these have also been referred to as "Rathke pouch tumors" or "hypophyseal duct tumors."</p><p>The epidemiology, pathology, diagnosis, management, and outcomes after treatment of craniopharyngiomas are reviewed here.</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>In the United States, an estimated 350 new cases of craniopharyngioma are diagnosed each year, resulting in an age-adjusted incidence of 0.19 per 100,000 persons [<a href="#rid2">2</a>].</p><p>Craniopharyngiomas constitute approximately 1 to 3 percent of all brain tumors [<a href="#rid3">3,4</a>] and approximately 5 to 10 percent of brain tumors in children [<a href="#rid4">4,5</a>]. Elsewhere in the world, craniopharyngiomas are more common, particularly in Japan and some parts of Africa [<a href="#rid6">6,7</a>]. Craniopharyngiomas are approximately equally common in males and females.</p><p>There is a bimodal age distribution, with one peak in children between 5 and 14 years old and a second peak in adults between 50 and 75 years of age [<a href="#rid3">3</a>]. Adamantinomatous craniopharyngiomas are more common in children, while papillary craniopharyngiomas predominate in adults [<a href="#rid8">8</a>]. (See <a class="local">'Pathology and molecular genetics'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">PATHOLOGY AND MOLECULAR GENETICS</span><span class="headingEndMark"> — </span>Craniopharyngiomas usually arise along the pituitary stalk in the suprasellar region adjacent to the optic chiasm. A small percentage arises within the sella [<a href="#rid9">9,10</a>], and even fewer along the optic system or within the third ventricle [<a href="#rid11">11,12</a>].</p><p>Craniopharyngiomas are epithelial tumors. In the World Health Organization classification of central nervous system tumors, they are divided into two categories, adamantinomatous and papillary [<a href="#rid13">13</a>]. These histologically disparate types have distinct molecular genetics.</p><p>Adamantinomatous craniopharyngiomas are characterized by activation of the Wnt signaling pathway, and almost all harbor activating mutations in <em>CTNNB1,</em> the gene encoding β-catenin [<a href="#rid14">14-16</a>]. By contrast, papillary craniopharyngiomas commonly harbor mutations in the <em>BRAF</em> oncogene [<a href="#rid16">16</a>]. In the largest study to date, mutations in <em>CTNNB1</em> were identified in 96 percent of 53 adamantinomatous tumors, and <em>BRAF</em> V600E mutations were identified in 94 percent of 39 papillary tumors [<a href="#rid16">16</a>].</p><p>Although benign histologically, craniopharyngiomas are locally aggressive and frequently shorten life; many clinicians consider them low-grade malignancies. Most contain both solid and cystic components. The cysts are filled with turbid fluid that contains cholesterol crystals.</p><p>The prognostic importance of tumor type is uncertain; older series have found that these two histologic subtypes behave similarly with respect to resectability, sensitivity to radiation, and overall survival [<a href="#rid17">17,18</a>].</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Craniopharyngiomas grow slowly, and symptoms often are present for a year or more before the diagnosis is established [<a href="#rid19">19,20</a>]. A wide range of symptoms may be present. Symptoms reflect a tumor's precise location and its relationship to adjacent normal structures.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Visual symptoms</strong> – Visual symptoms are frequent, and visual field deficits on formal ophthalmologic assessment are present in most patients. These result from compression of the optic chiasm or nerves; the specific deficit depends upon the growth pattern of the tumor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endocrine abnormalities</strong> – Direct damage to or compression of normal structures can lead to a range of endocrine abnormalities. Frequently observed complications include arginine vasopressin deficiency (AVP-D, previously called central diabetes insipidus) and deficiencies of growth hormone, gonadotropin, thyroid-stimulating hormone, and adrenocorticotropic hormone in an estimated 75, 40, 25, and 25 percent of cases, respectively [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1">Growth failure, caused by either hypothyroidism or growth hormone deficiency, is the most common presentation in children. Sexual dysfunction is the most common endocrine manifestation in adults; almost 90 percent of men complain of erectile dysfunction, while most women have amenorrhea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Headache</strong> – Moderate to severe daily headaches are present in approximately 50 percent of patients at the time of diagnosis [<a href="#rid21">21</a>]. These may result from traction on pain-sensitive structures by the tumor itself, obstructive hydrocephalus from tumor compression of the third ventricle, or meningeal irritation by escaped cyst contents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other symptoms</strong> – Craniopharyngiomas can also cause other generalized symptoms, such as depression and slowed cognition, independent of any hormone deficiency. The presumed cause is extension of tumor into the frontal lobes, striatal and thalamic areas, or limbic system. Nausea, vomiting, and lethargy can accompany pressure-related headaches.</p><p></p><p class="headingAnchor" id="H5"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>At the time of diagnosis, craniopharyngiomas vary from small, solid, well-circumscribed masses to huge multilocular cysts that invade the sella turcica and displace neighboring cerebral structures.</p><p class="headingAnchor" id="H6"><span class="h2">Neuroimaging</span><span class="headingEndMark"> — </span>Preoperatively, the diagnosis of craniopharyngioma is usually suggested by the presence of a suprasellar enhancing mass about the pituitary stalk on magnetic resonance imaging (MRI) and/or computed tomography (CT). The mass often compresses, displaces, and adheres to adjacent structures, including the optic nerves and chiasm, arteries of the Circle of Willis, pituitary gland, and hypothalamus; larger tumors can compress the third ventricle, brainstem, and frontal and temporal lobes  (<a class="graphic graphic_diagnosticimage graphicRef133163" href="/d/graphic/133163.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef133162" href="/d/graphic/133162.html" rel="external">image 2</a>).</p><p>One or more cysts are present in approximately 75 percent of craniopharyngiomas. Calcification in the suprasellar region is seen in over 60 percent of patients with craniopharyngioma. A cystic, calcified parasellar lesion in a child is very likely to be an adamantinomatous craniopharyngioma. CT or plain skull radiographs can help distinguish adamantinomatous craniopharyngiomas from noncalcified suprasellar lesions, including papillary craniopharyngiomas, which are less likely to be calcified than adamantinomatous tumors [<a href="#rid22">22</a>].</p><p>Craniopharyngiomas must be distinguished from other tumors in the parasellar area (including pituitary macroadenoma, meningioma, optic glioma, germinoma, teratoma, lymphoma, metastasis), from nonneoplastic cysts (Rathke's, pars intermedia, and arachnoid), and from infiltrative disorders such as sarcoidosis and systemic histiocytosis [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses", section on 'Cysts'</a> and  <a class="medical medical_review" href="/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Pretreatment evaluation</span><span class="headingEndMark"> — </span>Since most patients with craniopharyngioma have at least partial hypopituitarism, endocrine testing, particularly of adrenal and thyroid function, is indicated before surgery. (See  <a class="medical medical_review" href="/d/html/6639.html" rel="external">"Diagnostic testing for hypopituitarism"</a> and  <a class="medical medical_review" href="/d/html/154.html" rel="external">"Determining the etiology of adrenal insufficiency in adults"</a>.)</p><p>A detailed neuroophthalmologic examination including visual field testing helps to determine the severity of compression of the optic pathways and establishes a presurgical baseline. (See  <a class="medical medical_review" href="/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses", section on 'Visual defects'</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Historically, the optimal treatment of craniopharyngiomas has been controversial and included two basic approaches: aggressive surgery with an attempt to achieve complete resection at diagnosis versus a more conservative surgical approach that uses adjuvant radiation therapy (RT) to treat residual disease [<a href="#rid23">23</a>].</p><p>Major advances in neurosurgical techniques have significantly decreased the morbidity and mortality associated with resection, making aggressive resection feasible in more cases. At the same time, improvements in RT techniques have permitted more accurate delivery of radiation to the tumor target, while minimizing radiation damage to normal structures, and molecularly targeted therapies have emerged for papillary tumors. (See <a class="local">'Surgical approach'</a> below and <a class="local">'Radiation therapy'</a> below and <a class="local">'Targeted therapy for BRAF-mutant tumors'</a> below.)</p><p>An experienced multidisciplinary team (neurosurgery, radiation oncology, neuro-oncology, endocrinology, ophthalmology, neuroradiology, and neuropathology) is essential for the optimal treatment of both pediatric and adult patients with craniopharyngiomas [<a href="#rid5">5,20,24</a>].</p><p class="headingAnchor" id="H3366469998"><span class="h2">Multidisciplinary planning</span><span class="headingEndMark"> — </span>Suspected craniopharyngioma requires multidisciplinary input from neurosurgery, radiation oncology, and oncology for optimal treatment sequencing. With the discovery of effective targeted therapies for <em>BRAF</em>-mutant papillary craniopharyngioma, which accounts for the majority of craniopharyngiomas diagnosed in adulthood, it is particularly important to review cases of suspected craniopharyngioma preoperatively.</p><p class="headingAnchor" id="H9"><span class="h2">Surgical approach</span></p><p class="headingAnchor" id="H3024804418"><span class="h3">High suspicion for <i>BRAF</i>-mutant tumor</span><span class="headingEndMark"> — </span>When neuroimaging suggests craniopharyngioma, the patient has clinical characteristics suggestive of a papillary subtype (eg, adult age group, lack of tumor calcification), and severe, mass-related symptoms are not present, surgical options range from biopsy to gross total resection, and treatment decisions should be individualized with multidisciplinary input before surgery.</p><p>A transsphenoidal approach is often sufficient to obtain diagnostic tissue, and if papillary histology is confirmed, <em>BRAF-</em>targeted therapy is an option that can sometimes result in dramatic tumor reduction. This strategy potentially avoids the need for more aggressive surgery, radiation of larger fields, and their complications. (See <a class="local">'Targeted therapy for BRAF-mutant tumors'</a> below.)</p><p>On the other hand, use of <em>BRAF</em>-targeted therapy can be limited due to treatment toxicity and poor long-term tolerance. In addition, discontinuation of drug therapy is often followed by tumor regrowth. Thus, whereas <em>BRAF</em>-targeted therapy can help reduce aggressive neurosurgical risk, it does not replace the role of adjuvant radiation therapy, such that a safe gross total resection, when possible, is always preferred [<a href="#rid25">25</a>]. Caution should also be taken when combining <em>BRAF</em>-targeted therapy and cranial irradiation because of increased risk for neurologic toxicity [<a href="#rid26">26,27</a>].</p><p class="headingAnchor" id="H1377439380"><span class="h3">Low suspicion for <i>BRAF</i>-mutant tumor</span><span class="headingEndMark"> — </span>More aggressive surgery is indicated in almost all cases in which biopsy reveals an adamantinomatous craniopharyngioma or symptoms warrant relief of mass effect (eg, impending severe visual loss or brain herniation).</p><p>The goals of surgery are to establish the diagnosis, alleviate mass-related symptoms, and remove as much tumor as is safely possible. Complete resection may be limited by adherence of tumor to critical neural and vascular structures. Some neurosurgeons advocate cyst drainage to reduce neural compression and limited resection of solid tumor in anticipation of irradiation of residual tumor. Others advocate more aggressive surgery, arguing that the initial operation offers the best chance for surgical cure with the lowest risk of neurologic injury [<a href="#rid25">25,28,29</a>]. Gross total resections are durably curative without the need for additional radiation therapy and avoid radiation-associated late effects such as panhypopituitarism.</p><p>Preoperative management should include treatment of disease-related complications that could increase the risk associated with surgery:</p><p class="bulletIndent1"><span class="glyph">●</span>Endocrine function should be assessed and significant abnormalities corrected prior to surgery if possible. (See  <a class="medical medical_review" href="/d/html/6639.html" rel="external">"Diagnostic testing for hypopituitarism"</a> and  <a class="medical medical_review" href="/d/html/6640.html" rel="external">"Treatment of hypopituitarism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Significant peritumoral edema should be treated, and increased intracranial pressure should be controlled. (See  <a class="medical medical_review" href="/d/html/1659.html" rel="external">"Evaluation and management of elevated intracranial pressure in adults"</a> and  <a class="medical medical_review" href="/d/html/5182.html" rel="external">"Management of vasogenic edema in patients with primary and metastatic brain tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hydrocephalus may require temporary cerebrospinal fluid (CSF) diversion through an external ventricular drain. Permanent shunting may be needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a large cystic component of their tumor may require cyst aspiration prior to surgery to reduce mass effect or relieve obstructive hydrocephalus. (See <a class="local">'Cyst management'</a> below.)</p><p></p><p>The choice of treatment, the goals of surgery, and the surgical approach should be individualized for each patient. Considerations include the following: patient age, neurologic deficit, medical condition, and preference; tumor location, size, extension, consistency, and prior therapy; the institution's capabilities; and the surgeon's experience. The goals of surgery are usually to obtain pathologically diagnostic tissue, alleviate symptoms and neurologic deficits, relieve any obstructive hydrocephalus, decompress the optic nerves and chiasm, and remove as much of the tumor as possible without causing new neurologic or endocrine dysfunction.</p><p>Surgical strategy in children is particularly controversial. The benefit of gross total resection of craniopharyngioma in terms of quality of life in children is disputed [<a href="#rid30">30,31</a>]. This lack of certainty of benefit warrants cautious surgery, particularly in the region of the hypothalamus, since damage to this area from either preoperative involvement or surgery is a major predictor of poor quality-of-life outcomes [<a href="#rid32">32,33</a>]. Although more conservative surgery often results in residual tumor with the potential to regrow, the likelihood of regrowth can be reduced substantially by focal RT [<a href="#rid34">34,35</a>]. This benefit likely exceeds the risk of radiation-induced injury to the diencephalon, malignant change in the residual tumor or surrounding brain, or local scarring that might complicate any subsequent surgery.</p><p>Choice of surgical approach depends upon the location of the tumor. Intrasellar tumors are most readily removed transsphenoidally. An extended endonasal, endoscopic, transsphenoidal approach can access not just sellar tumors, but also suprasellar tumors including some that extend into the third ventricle  (<a class="graphic graphic_diagnosticimage graphicRef143230" href="/d/graphic/143230.html" rel="external">image 3</a>) [<a href="#rid28">28,36-38</a>]. This approach is more difficult when the interval between the diaphragma sellae and optic chiasm is limited and is contraindicated for tumors restricted to the third ventricle. Some third ventricular tumors can be exposed via craniotomy, from below, through the lamina terminalis or, from above, through the foramen of Monro.</p><p>Other limitations of the extended endonasal approach include extension of tumor lateral to the internal carotid arteries or above the anterior communicating artery complex, regions that may be accessed by simultaneous pterional or subfrontal craniotomy, respectively [<a href="#rid37">37</a>].</p><p>Preoperatively, the relation of the tumor to the pituitary stalk and chiasm (pre- or postinfundibular and pre- or postchiasmal) should be noted; diffusion tensor imaging tractography may be helpful [<a href="#rid39">39</a>]. In all cases, the surgeon should seek to identify and preserve the pituitary stalk, avoid manipulation of the optic chiasm, and refrain from dissection of tumor invading the hypothalamus  (<a class="graphic graphic_picture graphicRef143231" href="/d/graphic/143231.html" rel="external">picture 1</a>). Even with these precautions, postoperative hypothalamic dysfunction can occur, particularly with retrochiasmatic tumors that involve the posterior hypothalamus. While several small retrospective studies suggest that rates of obesity and arginine vasopressin deficiency (AVP-D) may be lower in patients treated with more conservative surgical approaches [<a href="#rid40">40-42</a>], prospective studies with long-term follow-up are needed to better compare the full range of outcomes with various contemporary surgical and RT techniques.</p><p class="headingAnchor" id="H2114167355"><span class="h2">Targeted therapy for <i>BRAF</i>-mutant tumors</span><span class="headingEndMark"> — </span>All craniopharyngiomas should be tested for <em>BRAF</em> V600E mutations by immunohistochemistry or sequencing to determine whether targeted therapy is a rational option as first-line therapy or, for previously diagnosed and treated tumors, as therapy for recurrence. Nearly all papillary craniopharyngiomas have <em>BRAF</em> V600E mutations. (See <a class="local">'Pathology and molecular genetics'</a> above.)</p><p>For patients with newly diagnosed <em>BRAF</em>-mutant papillary craniopharyngioma, a trial of BRAF/mitogen-activated protein kinase kinase (MEK) inhibition can be considered before proceeding with definitive RT or an attempt at maximal resection. <em>BRAF</em>-mutant craniopharyngiomas are highly responsive to BRAF inhibition, typically within the first two to three months of therapy [<a href="#rid22">22,43,44</a>]. BRAF/MEK combination therapy (eg, <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> plus <a class="drug drug_general" data-topicid="105354" href="/d/drug information/105354.html" rel="external">cobimetinib</a> or <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>) is preferred because the MEK inhibitor reduces both off-target side effects and treatment resistance related to the paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway seen with first-generation BRAF inhibitors.</p><p>After four to six cycles of combined targeted therapy, further treatment should be individualized after discussion of the potential risks and benefits of RT, surgery, continued targeted therapy, and observation. Any of these four options may be reasonable depending on clinical circumstances and the results of further studies.</p><p>This approach is supported by the results of a cooperative group trial of the Alliance for Clinical Trials in Oncology. In this multicenter single-arm phase 2 study, 16 adult patients (aged 33 to 83 years, median age of 49.5 years) with biopsy-confirmed <em>BRAF </em>V600E-mutant papillary craniopharyngioma (≥10 mm in diameter) and no prior therapy were treated with <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> (960 mg orally twice daily) and <a class="drug drug_general" data-topicid="105354" href="/d/drug information/105354.html" rel="external">cobimetinib</a> (60 mg once daily on days 1 to 21 of every 28-day cycle) [<a href="#rid43">43</a>]. The protocol prespecified that patients would receive definitive surgery or radiation therapy after four cycles of vemurafenib plus cobimetinib, but exceptions were made for selected patients who appeared to have benefited from treatment, had serious risks for additional treatment, or declined subsequent therapy.</p><p>Overall, 15 out of 16 patients (94 percent) had a partial or complete volumetric response to four cycles of targeted therapy [<a href="#rid43">43</a>]. The one patient who did not respond discontinued therapy after only eight days due to toxicity. Decrease in both cystic and solid components was seen. Among responders, reduction in tumor volume ranged from 68 to 99 percent (median of 91 percent). At completion of the protocol-specified targeted therapy, eight patients received RT (six RT alone, one RT followed by surgery and one RT followed by <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a>), one patient continued <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> plus <a class="drug drug_general" data-topicid="105354" href="/d/drug information/105354.html" rel="external">cobimetinib</a> off-protocol, and seven patients had no further therapy. Estimated progression-free survival rates at 12 and 24 months were 87 and 57 percent, respectively, and overall survival at 24 months was 100 percent. Among the seven patients who stopped therapy, six had no progression at a median follow-up of 23 months. Grade 3 adverse events occurred in 12 of 16 patients (75 percent), most commonly rash, and there were two grade 4 adverse events (hyperglycemia and elevated creatine kinase).</p><p class="headingAnchor" id="H10"><span class="h2">Radiation therapy</span><span class="headingEndMark"> — </span>RT is used to treat patients with residual disease after partial surgical resection or targeted therapy or to treat disease that has recurred despite surgery and/or targeted therapy [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H11"><span class="h3">RT techniques</span><span class="headingEndMark"> — </span>Contemporary RT techniques permit greater treatment precision and conformity. These approaches decrease, but do not eliminate, long-term toxicity by limiting the exposure of surrounding normal tissues to ionizing radiation [<a href="#rid46">46</a>]. Treatment techniques providing highly conformal, image-guided radiation include stereotactic radiotherapy (SRT) [<a href="#rid45">45,47-49</a>], intensity-modulated RT (IMRT), and proton beam therapy [<a href="#rid50">50-53</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Stereotactic techniques – SRT and stereotactic radiosurgery (SRS) utilize head fixation to establish a patient-specific coordinate system for imaging, treatment planning, and delivery. Imaging of applied fiducial markers or facial contours permits localization of the patient's head and tumor within this coordinate system, allowing precise delineation of the target treatment volume and accurate description of the planned radiation field. (See  <a class="medical medical_review" href="/d/html/7063.html" rel="external">"Stereotactic cranial radiosurgery"</a>.)</p><p></p><p class="bulletIndent1">SRT uses a fully fractionated treatment schedule, usually approximately 30 fractions to 54 Gy, to minimize damage to normal structures, while allowing coverage of a relatively large target volume. SRS uses one to five fractions; it is an acceptable alternative to more extensively fractionated radiotherapy for small tumors or small focal postoperative residuals that are safely distant from the optic pathway to not risk visual injury. For both SRT and SRS, priority is taken to keep the dose within the tolerance of the optic nerves, chiasm, and tracts.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intensity-modulated RT – IMRT is a sophisticated software planning technique that uses dynamic delivery of radiation to optimize the delivery of radiation to irregularly shaped volumes. This technique can be added to SRT or SRS to shape the beam to the irregular contours of the tumor. (See  <a class="medical medical_review" href="/d/html/89528.html" rel="external">"Radiation therapy techniques in cancer treatment", section on 'Intensity-modulated radiation therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Proton beam RT – Heavy particle irradiation techniques such as proton beam use charged particles rather than photons to deliver high doses of radiation to the target volume while limiting the "scatter" dose received by surrounding tissues. There is minimal radiation exposure beyond the Bragg peak, where the protons come to a halt and deliver their energy. This can be advantageous in treating tumors very near critical structures [<a href="#rid53">53</a>]; however, the margin of this benefit is far lower with contemporary higher precision stereotactic localization and conformal photon technique with IMRT. (See  <a class="medical medical_review" href="/d/html/89528.html" rel="external">"Radiation therapy techniques in cancer treatment", section on 'Particle therapy'</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h3">Radiation dose</span><span class="headingEndMark"> — </span>For fractionated treatment schedules using conformal RT techniques, standard dose is 54 Gy at 1.8 Gy per fraction to best balance safety of normal tissue radiation exposure with sufficient dose to be durably effective. In a retrospective series, the recurrence rate was significantly higher in patients receiving ≤54 Gy compared with higher doses (50 versus 15 percent) [<a href="#rid54">54</a>].</p><p>Patients with cystic craniopharyngioma undergoing radiotherapy must be reimaged routinely during the course of treatment. Cysts can enlarge during radiation and necessitate revision of the radiotherapy plan.</p><p class="headingAnchor" id="H13"><span class="h2">Cyst management</span><span class="headingEndMark"> — </span>Attempts to decrease cyst size are often indicated when a cyst compresses visual or hypothalamic structures or causes symptomatic obstruction of the third ventricle. Surgical removal of the tumor is the most definitive treatment. Cysts recurrent after surgery may be treated in several ways.</p><p class="headingAnchor" id="H14"><span class="h3">Aspiration</span><span class="headingEndMark"> — </span>Percutaneous aspiration of cyst contents can alleviate symptoms; intermittent aspiration may be needed when cyst excision is not feasible [<a href="#rid55">55,56</a>]. This can be facilitated by placement of an Ommaya reservoir [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H15"><span class="h3">Intracystic irradiation</span><span class="headingEndMark"> — </span>Solitary or multicystic tumors can be treated with intracavitary irradiation via stereotactically applied radioisotopes [<a href="#rid58">58-63</a>]. Beta-emitting isotopes such as yttrium-90 (90Yt), rhenium-186 (186Rh), and phosphorus-32 (32P) are preferred because of the limited penetrance of the emitted energy and their relative ease of handling.</p><p class="headingAnchor" id="H16"><span class="h3">Intracystic chemotherapy</span><span class="headingEndMark"> — </span>Alternatively, intracystic instillation of chemotherapeutic and immunologic agents has been tried [<a href="#rid64">64</a>]. In one series, intracystic <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> produced complete remission of disease in five of 17 children and a median progression-free interval of 1.8 years with limited toxicity [<a href="#rid65">65</a>]. Intracystic installation of interferon alpha has also been used [<a href="#rid66">66-68</a>]. This approach may postpone the need for RT or aggressive surgery.</p><p class="headingAnchor" id="H17"><span class="h2">Disease control</span><span class="headingEndMark"> — </span>Complete resection is the ideal outcome of surgery. Untreated residual tumor will likely resume enlargement with solid tumor growth and/or cyst expansion. Improvements in surgical techniques have increased the frequency with which a complete resection can be achieved without excessive morbidity or mortality [<a href="#rid28">28,69,70</a>]. However, the benefits of surgery must be balanced against treatment-related morbidity [<a href="#rid38">38</a>]. (See <a class="local">'Surgical approach'</a> above.)</p><p>RT, widely used as an adjuvant following subtotal resection, significantly reduces the risk of local recurrence [<a href="#rid71">71-76</a>]. The impact of adjuvant RT on overall survival is less clear; RT may be less effective as salvage therapy for recurrent disease. There are no randomized trials that compare adjuvant RT with observation after surgery followed by salvage RT for recurrent disease.</p><p>The following reports from large series illustrate the range of findings using contemporary surgical and RT techniques:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis showed better outcomes with the extended endoscopic endonasal approach than with craniotomy or a limited transsphenoidal approach [<a href="#rid77">77</a>]. Total tumor resection was more likely; improvement of vision was more common; and rates of worsening of vision, pituitary dysfunction, AVP-D, hemorrhage, and mortality were lower. The rate of CSF leakage, however, is higher with endonasal approaches. A separate study found higher rates of postoperative AVP-D and lower rates of visual improvement with transcranial resections; hypothalamic injury was common with both approaches [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one series of 65 pediatric tumors treated surgically, mostly through a transsphenoidal route with intent of complete removal, gross total resection was achieved for 98 percent of tumors treated initially and for 25 percent of recurrent tumors [<a href="#rid28">28,38</a>]. The rate of recurrence after initial gross total resection was 7 percent. Newly diagnosed obesity occurred in 9 and 21 percent of patients after initial and recurrent surgery, respectively [<a href="#rid28">28,38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Seventy-five patients treated for craniopharyngioma at a single institution over a 27-year period underwent an attempt at gross total excision [<a href="#rid71">71</a>]. Eighteen of the 27 patients in whom only a subtotal resection was possible received adjuvant RT. RT was also given to 22 patients with a local relapse following surgery alone. At a median follow-up of 7.6 years, the 10-year local control rate was significantly better for the patients with subtotal resection plus RT than for the 57 patients treated with surgery alone, 48 of whom originally had a complete resection (84 versus 42 percent). The overall survival rate for the entire cohort was 85 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Of 121 patients treated between 1963 and 2002, 19 underwent gross total removal, 84 partial resection, and 9 cyst evacuation [<a href="#rid72">72</a>]. All patients who received gross total resection were free of recurrence at 10 years. Among those managed with partial resection, the 10-year recurrence-free rates were 77 and 38 percent, with and without postoperative RT, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SRT (52.2 Gy in 1.8 Gy fractions) was used to treat 40 patients (28 with recurrent disease, 12 as an adjuvant after surgery) [<a href="#rid47">47</a>]. At a median follow-up of 98 months, local control was 100 percent at 10 years and overall survival was 89 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Forty-six patients with craniopharyngioma underwent 51 courses of treatment with SRS for residual or recurrent craniopharyngioma (median tumor volume 1.0 cm<sup>3</sup>) [<a href="#rid49">49</a>]. At a mean follow-up of over five years, the five-year overall and progression-free survival rates were 97 and 92 percent, respectively.</p><p></p><p class="headingAnchor" id="H18"><span class="h2">Treatment complications</span><span class="headingEndMark"> — </span>Numerous complications can accompany treatment of craniopharyngioma. These may be specific to surgery or radiation therapy, reflect the combined adverse effects of the two, or represent aggregate effects of the tumor and its treatment. Deficits can be caused by injury to critical neural structures by tissue manipulation; vascular compromise during surgery; or radiation-induced neural toxicity, necrosis, or vasculopathy [<a href="#rid79">79</a>].</p><p>Surgery-specific complications include infection, bleeding, and CSF leakage [<a href="#rid80">80</a>]. Radiation-specific complications include delayed induction of atherosclerosis and vascular anomalies. The potential for treatment to cause devastating deficits mandates thoughtful coordinated planning by a multidisciplinary team of experienced specialists.</p><p class="headingAnchor" id="H19"><span class="h3">Endocrine</span><span class="headingEndMark"> — </span>Endocrine abnormalities can arise from or be exacerbated by treatment; these likely contribute to the increased mortality of patients with craniopharyngioma [<a href="#rid79">79,81</a>]. They reflect injury to the hypothalamus, pituitary stalk, or both.</p><p class="bulletIndent1"><span class="glyph">●</span>Altered pituitary function, present in most patients, can manifest as panhypopituitarism or isolated hypogonadism, hypothyroidism, adrenal insufficiency, and/or growth hormone deficiency [<a href="#rid82">82,83</a>]. For patients treated in childhood, the 10-year cumulative risk of each of these exceeds 70 percent [<a href="#rid42">42,83</a>]. (See  <a class="medical medical_review" href="/d/html/6637.html" rel="external">"Clinical manifestations of hypopituitarism"</a> and  <a class="medical medical_review" href="/d/html/6639.html" rel="external">"Diagnostic testing for hypopituitarism"</a> and  <a class="medical medical_review" href="/d/html/6640.html" rel="external">"Treatment of hypopituitarism"</a>.)</p><p></p><p class="bulletIndent1">Growth hormone replacement initiated in childhood increases height and does not appear to have an adverse impact on overall survival and progression-free survival [<a href="#rid84">84</a>]. Growth hormone administration beginning one year after diagnosis may be associated with early improvements in quality of life when measured three years after diagnosis [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypothalamic endocrine dysfunction can include hyperphagia, disabling obesity [<a href="#rid86">86,87</a>], metabolic syndrome with type 2 diabetes mellitus, nonalcoholic liver disease [<a href="#rid88">88</a>], disorders of sleep and temperature regulation, and AVP-D. (See  <a class="medical medical_review" href="/d/html/2373.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"</a> and  <a class="medical medical_review" href="/d/html/2313.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Treatment"</a> and  <a class="medical medical_review" href="/d/html/5377.html" rel="external">"Obesity in adults: Etiologies and risk factors", section on 'Hypothalamic obesity'</a>.)</p><p></p><p class="headingAnchor" id="H20"><span class="h3">Neurologic</span><span class="headingEndMark"> — </span>Common nonendocrine neurologic complications include:</p><p class="bulletIndent1"><span class="glyph">●</span>Visual deficits – Most patients have visual field deficits prior to treatment. These may be exacerbated acutely by surgery-induced stroke or chronically by radiation-induced optic neuritis or vasculopathy. Diplopia can result from injury to oculomotor nerves during surgical approaches.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurocognitive deficits – Diminished awareness, slowed thought, and memory loss can occur. Severe memory loss can follow injury to the fornix due to some cranial approaches or excessively aggressive dissection of tumor from the hypothalamus bordering the third ventricle [<a href="#rid79">79,89,90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Behavioral problems – Apathy, lethargy, and depression can reflect primary neural loss or secondary hormonal deficiency [<a href="#rid91">91</a>].</p><p></p><p class="headingAnchor" id="H22"><span class="h3">Vascular abnormalities</span><span class="headingEndMark"> — </span>Radiation therapy can increase risk of ischemic vascular disease and development of cerebrovascular anomalies [<a href="#rid81">81,82</a>]. In a retrospective series of 123 patients with craniopharyngioma treated with multimodality therapy, 14 patients experienced transient ischemic attack or stroke; of these, two were in the immediate postoperative period and 12 occurred at a median of 4.4 years after radiation [<a href="#rid82">82</a>]. A small cross-sectional cohort study observed a trend suggesting that long-term replacement of growth hormone may reduce the risk of stroke [<a href="#rid92">92</a>].</p><p>A variety of vascular abnormalities can follow irradiation of a craniopharyngioma, particularly in children. In one series, among 20 patients who underwent imaging following radiation treatment, six had abnormalities, including temporal cavernomas, moyamoya syndrome, aneurysms, and decreases in arterial caliber [<a href="#rid92">92,93</a>].</p><p>Cerebrovascular complications of cranial irradiation are reviewed in more detail separately. (See  <a class="medical medical_review" href="/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation", section on 'Cerebrovascular effects'</a>.)</p><p class="headingAnchor" id="H23"><span class="h3">Secondary tumors</span><span class="headingEndMark"> — </span>RT to treat craniopharyngiomas has been associated with secondary development of meningioma and malignant glial tumors [<a href="#rid82">82,83,94</a>]. (See  <a class="medical medical_review" href="/d/html/5214.html" rel="external">"Risk factors for brain tumors", section on 'Ionizing radiation'</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">RECURRENT DISEASE</span><span class="headingEndMark"> — </span>Most tumor recurrences are local; surgery, whether used initially or deferred, may be indicated, as may be radiosurgery, if enlarging focal solid disease rather than cyst expansion is the problem [<a href="#rid95">95</a>]. In addition, molecularly targeted therapy is an option in <em>BRAF</em>-mutant tumors at recurrence [<a href="#rid96">96-98</a>]. (See <a class="local">'Targeted therapy for BRAF-mutant tumors'</a> above.)</p><p>Malignant histologic transformation is rare but has been reported, usually after multiple recurrences and radiation therapy (RT) [<a href="#rid99">99,100</a>]. Remote recurrences can occur, possibly as a consequence of seeding through the cerebrospinal fluid (CSF) during surgery [<a href="#rid101">101-104</a>]. Morbidity and mortality are higher with treatment of recurrent disease than with initial therapy [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H25"><span class="h1">POSTTREATMENT FOLLOW-UP</span><span class="headingEndMark"> — </span>There are no evidence-based guidelines for follow-up after initial therapy. Key features of patient management include:</p><p class="bulletIndent1"><span class="glyph">●</span>Neuroimaging with magnetic resonance imaging (MRI), initially every 3 to 12 months, depending upon the residual tumor, tumor cyst, and concern for potential early progression. When radiation therapy is used adjuvantly, a durable effect often takes months to set in. The duration of imaging follow-up depends upon the extent of initial surgery, the presence or absence of residual tumor, and symptomatology. Cases of recurrence after decades of tumor quiescence suggest the need for long-term follow-up.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring of endocrine function with replacement hormone therapy as needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Formal assessment of visual function including visual field testing postoperatively and annually thereafter.</p><p></p><p class="headingAnchor" id="H985761160"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The long-term prognosis following treatment is influenced both by the ability to control tumor and the development of treatment-related complications. Rates of 10-year overall survival range from 80 to 96 percent [<a href="#rid72">72,82,83</a>].</p><p>Despite this, late mortality is increased in patients even without tumor progression; this may reflect complications of treatment, particularly in survivors of childhood craniopharyngioma [<a href="#rid105">105</a>].</p><p>In one series of 41 patients treated over 37 years, there were nine deaths (22 percent) overall [<a href="#rid106">106</a>]. One of these occurred between 10 and 20 years, and three occurred more than 20 years after presentation. These four deaths resulted not from uncontrolled tumor progression but from arginine vasopressin deficiency (AVP-D), pontine infarction, panhypopituitarism, and liver failure.</p><p>Another population-based study of 307 patients with craniopharyngioma followed for a median of nine years found that individuals with craniopharyngioma had a three- to fivefold increase in expected mortality compared with that of the general population [<a href="#rid81">81</a>]. The major contributors to excess mortality were cerebrovascular disease (standardized mortality ratio [SMR] 5.1), type 2 diabetes mellitus (SMR 5.6), myocardial infarction (SMR 2.1), and severe infection (SMR 5.9).</p><p>Many series have relatively short follow-up; older studies with longer follow-up may not be informative regarding the results of newer surgical and radiation therapy (RT) techniques. Patients treated with contemporary techniques may fare better.</p><p class="headingAnchor" id="H958687252"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/130511.html" rel="external">"Society guideline links: Primary brain tumors"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Craniopharyngiomas are rare suprasellar brain tumors arising from the remnants of Rathke’s pouch. There is a bimodal age distribution, with peak incidence between 5 and 14 years and later between 50 and 75 years of age. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology and genetics</strong> – Histologically, craniopharyngiomas are either adamantinomatous (more common in childhood) or papillary (predominant in adults). All tumors should be tested for <em>BRAF</em> V600E mutations by immunohistochemistry or sequencing. Nearly all papillary craniopharyngiomas have <em>BRAF</em> V600E mutations. (See <a class="local">'Pathology and molecular genetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Craniopharyngiomas are slow-growing tumors that usually arise along the pituitary stalk in the suprasellar region adjacent to the optic chiasm. Common presenting symptoms include visual changes, endocrine abnormalities, and headache. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1">Neuroimaging shows a suprasellar enhancing mass  (<a class="graphic graphic_diagnosticimage graphicRef133163" href="/d/graphic/133163.html" rel="external">image 1</a>), often cystic and, in the case of adamantinomatous tumors, calcified  (<a class="graphic graphic_diagnosticimage graphicRef133162" href="/d/graphic/133162.html" rel="external">image 2</a>). (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multidisciplinary planning</strong> – Individuals should be managed by a multidisciplinary team experienced in the treatment of craniopharyngioma that includes neurosurgery, radiation oncology, neuro-oncology, endocrinology, ophthalmology, neuroradiology, and neuropathology. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical management</strong> – When neuroimaging suggests craniopharyngioma in a patient with clinical characteristics suggestive of a papillary subtype (eg, adult age, lack of tumor calcification) <strong>and</strong> there is an intent to offer <em>BRAF</em>-targeted therapy to lessen need for risky surgery and large radiation fields, biopsy or conservative resection is an alternative to upfront aggressive surgery. However, decisions should be individualized, since <em>BRAF</em> therapy does not replace the role of adjuvant radiation and is sometimes poorly tolerated, and gross total resections, when safe, can be curative and obviate the need for adjuvant therapy of any kind. (See <a class="local">'High suspicion for BRAF-mutant tumor'</a> above.)</p><p></p><p class="bulletIndent1">For all other patients, initial management involves surgical resection to establish diagnosis, alleviate mass-related symptoms, and remove as much tumor as is safely possible. (See <a class="local">'Low suspicion for BRAF-mutant tumor'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>BRAF</em></strong><strong>-mutant tumors</strong> – For most patients with newly diagnosed <em>BRAF</em>-mutant papillary craniopharyngioma who have residual disease after surgical management, we suggest treatment with <em>BRAF</em>-targeted therapy (eg, <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>/<a class="drug drug_general" data-topicid="105354" href="/d/drug information/105354.html" rel="external">cobimetinib</a> or <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a>/<a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>) and/or adjuvant radiation therapy (RT), rather than watchful waiting (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Adjuvant RT improves local control and may be associated with less morbidity than use as a salvage therapy. (See <a class="local">'Radiation therapy'</a> above.)</p><p></p><p class="bulletIndent2">For patients who ele<em>ct BRAF</em>-targeted therapy, treatment decisions after four to six cycles should be individualized after discussion of the potential risks and benefits of RT, surgery, continued targeted therapy, and observation. (See <a class="local">'Targeted therapy for BRAF-mutant tumors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>All other tumors</strong> – For most other patients, postoperative decisions are individualized based on the extent of tumor residual, patient age and comorbidities, and the potential risks of RT. RT after subtotal resection reduces the risk of recurrence. Some patients require additional procedures to manage symptomatic cysts. (See <a class="local">'Radiation therapy'</a> above and <a class="local">'Cyst management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment complications</strong> – A wide range of endocrine and neurologic complications are observed in patients with craniopharyngioma following treatment; these likely contribute to the increased mortality of patients with craniopharyngioma and thus the rationale for lifelong surveillance for these patients. (See <a class="local">'Treatment complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The long-term prognosis following treatment is influenced both by the ability to control tumor and the development of treatment-related complications. In long-term follow-up studies, rates of 10-year overall survival range from 80 to 96 percent. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Petito CK, DeGirolami U, Earle KM. Craniopharyngiomas: a clinical and pathological review. Cancer 1976; 37:1944.</a></li><li><a class="nounderline abstract_t">Ostrom QT, Cioffi G, Waite K, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. Neuro Oncol 2021; 23:iii1.</a></li><li><a class="nounderline abstract_t">Bunin GR, Surawicz TS, Witman PA, et al. The descriptive epidemiology of craniopharyngioma. J Neurosurg 1998; 89:547.</a></li><li><a class="nounderline abstract_t">Jane JA Jr, Laws ER. Craniopharyngioma. Pituitary 2006; 9:323.</a></li><li><a class="nounderline abstract_t">Garrè ML, Cama A. Craniopharyngioma: modern concepts in pathogenesis and treatment. Curr Opin Pediatr 2007; 19:471.</a></li><li><a class="nounderline abstract_t">Stiller CA, Nectoux J. International incidence of childhood brain and spinal tumours. Int J Epidemiol 1994; 23:458.</a></li><li><a class="nounderline abstract_t">Izuora GI, Ikerionwu S, Saddeqi N, Iloeje SO. Childhood intracranial neoplasms Enugu, Nigeria. West Afr J Med 1989; 8:171.</a></li><li class="breakAll">WHO Classification of Tumours of the Central Nervous System, 4th ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), International Agency for Research on Cancer, 2016.</li><li><a class="nounderline abstract_t">Laws ER Jr. Transsphenoidal microsurgery in the management of craniopharyngioma. J Neurosurg 1980; 52:661.</a></li><li><a class="nounderline abstract_t">NORTHFIELD DW. Rathke-pouch tumours. Brain 1957; 80:293.</a></li><li><a class="nounderline abstract_t">Bollati A, Giunta F, Lenzi A, Marini G. Third ventricle intrinsic craniopharingioma. Case report. J Neurosurg Sci 1974; 18:216.</a></li><li><a class="nounderline abstract_t">Cashion EL, Young JM. Intraventricular craniopharyngioma. Report of two cases. J Neurosurg 1971; 34:84.</a></li><li class="breakAll">WHO Classification of Tumours Editorial Board. Thoracic Tumours. In: WHO Classification of Tumours, 5th ed, IARC Publications, 2021. Vol 5.</li><li><a class="nounderline abstract_t">Buslei R, Nolde M, Hofmann B, et al. Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol 2005; 109:589.</a></li><li><a class="nounderline abstract_t">Sekine S, Shibata T, Kokubu A, et al. Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol 2002; 161:1997.</a></li><li><a class="nounderline abstract_t">Brastianos PK, Taylor-Weiner A, Manley PE, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 2014; 46:161.</a></li><li><a class="nounderline abstract_t">Weiner HL, Wisoff JH, Rosenberg ME, et al. Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery 1994; 35:1001.</a></li><li><a class="nounderline abstract_t">Crotty TB, Scheithauer BW, Young WF Jr, et al. Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg 1995; 83:206.</a></li><li><a class="nounderline abstract_t">Duff J, Meyer FB, Ilstrup DM, et al. Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery 2000; 46:291.</a></li><li><a class="nounderline abstract_t">Garnett MR, Puget S, Grill J, Sainte-Rose C. Craniopharyngioma. Orphanet J Rare Dis 2007; 2:18.</a></li><li><a class="nounderline abstract_t">Khan RB, Merchant TE, Boop FA, et al. Headaches in children with craniopharyngioma. J Child Neurol 2013; 28:1622.</a></li><li><a class="nounderline abstract_t">Juratli TA, Jones PS, Wang N, et al. Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. Cancer 2019; 125:2910.</a></li><li><a class="nounderline abstract_t">Lober RM, Harsh GR 4th. A perspective on craniopharyngioma. World Neurosurg 2013; 79:645.</a></li><li><a class="nounderline abstract_t">Honegger J, Tatagiba M. Craniopharyngioma surgery. Pituitary 2008; 11:361.</a></li><li><a class="nounderline abstract_t">Godil SS, Tosi U, Gerges M, et al. Long-term tumor control after endoscopic endonasal resection of craniopharyngiomas: comparison of gross-total resection versus subtotal resection with radiation therapy. J Neurosurg 2022; 136:1347.</a></li><li><a class="nounderline abstract_t">Patel KR, Chowdhary M, Switchenko JM, et al. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res 2016; 26:387.</a></li><li><a class="nounderline abstract_t">Kim JM, Miller JA, Kotecha R, et al. The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies. J Neurooncol 2017; 133:357.</a></li><li><a class="nounderline abstract_t">Yamada S, Fukuhara N, Yamaguchi-Okada M, et al. Therapeutic outcomes of transsphenoidal surgery in pediatric patients with craniopharyngiomas: a single-center study. J Neurosurg Pediatr 2018; 21:549.</a></li><li><a class="nounderline abstract_t">Bobeff EJ, Mathios D, Mistry AA, et al. Predictors of extent of resection and recurrence following endoscopic endonasal resection of craniopharyngioma. J Neurosurg 2023; 139:1235.</a></li><li><a class="nounderline abstract_t">Hidalgo ET, Orillac C, Kvint S, et al. Quality of life, hypothalamic obesity, and sexual function in adulthood two decades after primary gross-total resection for childhood craniopharyngioma. Childs Nerv Syst 2020; 36:281.</a></li><li><a class="nounderline abstract_t">Fjalldal S, Follin C, Gabery S, et al. Detailed assessment of hypothalamic damage in craniopharyngioma patients with obesity. Int J Obes (Lond) 2019; 43:533.</a></li><li><a class="nounderline abstract_t">Müller HL, Merchant TE, Warmuth-Metz M, et al. Craniopharyngioma. Nat Rev Dis Primers 2019; 5:75.</a></li><li><a class="nounderline abstract_t">Mortini P, Losa M, Pozzobon G, et al. Neurosurgical treatment of craniopharyngioma in adults and children: early and long-term results in a large case series. J Neurosurg 2011; 114:1350.</a></li><li><a class="nounderline abstract_t">Eveslage M, Calaminus G, Warmuth-Metz M, et al. The Postopera tive Quality of Life in Children and Adolescents with Craniopharyngioma. Dtsch Arztebl Int 2019; 116:321.</a></li><li><a class="nounderline abstract_t">Yang I, Sughrue ME, Rutkowski MJ, et al. Craniopharyngioma: a comparison of tumor control with various treatment strategies. Neurosurg Focus 2010; 28:E5.</a></li><li><a class="nounderline abstract_t">de Divitiis E, Cappabianca P, Cavallo LM, et al. Extended endoscopic transsphenoidal approach for extrasellar craniopharyngiomas. Neurosurgery 2007; 61:219.</a></li><li><a class="nounderline abstract_t">Koutourousiou M, Fernandez-Miranda JC, Wang EW, et al. The limits of transsellar/transtuberculum surgery for craniopharyngioma. J Neurosurg Sci 2018; 62:301.</a></li><li><a class="nounderline abstract_t">Taylor DG, Jane JA. Editorial. Endoscopic endonasal surgery for pediatric craniopharyngiomas. J Neurosurg Pediatr 2018; 21:545.</a></li><li><a class="nounderline abstract_t">Wang F, Jiang J, Zhang J, Wang Q. Predicting pituitary stalk position by in vivo visualization of the hypothalamo-hypophyseal tract in craniopharyngioma using diffusion tensor imaging tractography. Neurosurg Rev 2018; 41:841.</a></li><li><a class="nounderline abstract_t">Cohen M, Bartels U, Branson H, et al. Trends in treatment and outcomes of pediatric craniopharyngioma, 1975-2011. Neuro Oncol 2013; 15:767.</a></li><li><a class="nounderline abstract_t">Elowe-Gruau E, Beltrand J, Brauner R, et al. Childhood craniopharyngioma: hypothalamus-sparing surgery decreases the risk of obesity. J Clin Endocrinol Metab 2013; 98:2376.</a></li><li><a class="nounderline abstract_t">Van Schaik J, Schouten-van Meeteren AYN, Vos-Kerkhof E, et al. Treatment and outcome of the Dutch Childhood Craniopharyngioma Cohort study: First results after centralization of care. Neuro Oncol 2023; 25:2250.</a></li><li><a class="nounderline abstract_t">Brastianos PK, Twohy E, Geyer S, et al. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas. N Engl J Med 2023; 389:118.</a></li><li><a class="nounderline abstract_t">Blakeley JO, Shannon K. Precision Oncology for Papillary Craniopharyngioma. N Engl J Med 2023; 389:179.</a></li><li><a class="nounderline abstract_t">Minniti G, Esposito V, Amichetti M, Enrici RM. The role of fractionated radiotherapy and radiosurgery in the management of patients with craniopharyngioma. Neurosurg Rev 2009; 32:125.</a></li><li><a class="nounderline abstract_t">Jalali R, Gupta T, Goda JS, et al. Efficacy of Stereotactic Conformal Radiotherapy vs Conventional Radiotherapy on Benign and Low-Grade Brain Tumors: A Randomized Clinical Trial. JAMA Oncol 2017; 3:1368.</a></li><li><a class="nounderline abstract_t">Combs SE, Thilmann C, Huber PE, et al. Achievement of long-term local control in patients with craniopharyngiomas using high precision stereotactic radiotherapy. Cancer 2007; 109:2308.</a></li><li><a class="nounderline abstract_t">Kobayashi T. Long-term results of gamma knife radiosurgery for 100 consecutive cases of craniopharyngioma and a treatment strategy. Prog Neurol Surg 2009; 22:63.</a></li><li><a class="nounderline abstract_t">Niranjan A, Kano H, Mathieu D, et al. Radiosurgery for craniopharyngioma. Int J Radiat Oncol Biol Phys 2010; 78:64.</a></li><li><a class="nounderline abstract_t">Fitzek MM, Linggood RM, Adams J, Munzenrider JE. Combined proton and photon irradiation for craniopharyngioma: long-term results of the early cohort of patients treated at Harvard Cyclotron Laboratory and Massachusetts General Hospital. Int J Radiat Oncol Biol Phys 2006; 64:1348.</a></li><li><a class="nounderline abstract_t">Luu QT, Loredo LN, Archambeau JO, et al. Fractionated proton radiation treatment for pediatric craniopharyngioma: preliminary report. Cancer J 2006; 12:155.</a></li><li><a class="nounderline abstract_t">Bishop AJ, Greenfield B, Mahajan A, et al. Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity. Int J Radiat Oncol Biol Phys 2014; 90:354.</a></li><li><a class="nounderline abstract_t">Beddok A, Scher N, Alapetite C, et al. Proton therapy for adult craniopharyngioma: Experience of a single institution in 91 consecutive patients. Neuro Oncol 2023; 25:710.</a></li><li><a class="nounderline abstract_t">Regine WF, Kramer S. Pediatric craniopharyngiomas: long term results of combined treatment with surgery and radiation. Int J Radiat Oncol Biol Phys 1992; 24:611.</a></li><li><a class="nounderline abstract_t">McMurry FG, Hardy RW Jr, Dohn DF, et al. Long term results in the management of craniopharyngiomas. Neurosurgery 1977; 1:238.</a></li><li><a class="nounderline abstract_t">Ignelzi RJ, Squire LR. Recovery from anterograde and retrograde amnesia after percutaneous drainage of a cystic craniopharyngioma. J Neurol Neurosurg Psychiatry 1976; 39:1231.</a></li><li><a class="nounderline abstract_t">Gutin PH, Klemme WM, Lagger RL, et al. Management of the unresectable cystic craniopharyngioma by aspiration through an Ommaya reservoir drainage system. J Neurosurg 1980; 52:36.</a></li><li><a class="nounderline abstract_t">Julow J, Lányi F, Hajda M, et al. The radiotherapy of cystic craniopharyngioma with intracystic installation of 90Y silicate colloid. Acta Neurochir (Wien) 1985; 74:94.</a></li><li><a class="nounderline abstract_t">Voges J, Sturm V, Lehrke R, et al. Cystic craniopharyngioma: long-term results after intracavitary irradiation with stereotactically applied colloidal beta-emitting radioactive sources. Neurosurgery 1997; 40:263.</a></li><li><a class="nounderline abstract_t">Pollock BE, Lunsford LD, Kondziolka D, et al. Phosphorus-32 intracavitary irradiation of cystic craniopharyngiomas: current technique and long-term results. Int J Radiat Oncol Biol Phys 1995; 33:437.</a></li><li><a class="nounderline abstract_t">Van den Berge JH, Blaauw G, Breeman WA, et al. Intracavitary brachytherapy of cystic craniopharyngiomas. J Neurosurg 1992; 77:545.</a></li><li><a class="nounderline abstract_t">Barriger RB, Chang A, Lo SS, et al. Phosphorus-32 therapy for cystic craniopharyngiomas. Radiother Oncol 2011; 98:207.</a></li><li><a class="nounderline abstract_t">Yu X, Christ SM, Liu R, et al. Evaluation of Long-Term Outcomes and Toxicity After Stereotactic Phosphorus-32-Based Intracavitary Brachytherapy in Patients With Cystic Craniopharyngioma. Int J Radiat Oncol Biol Phys 2021; 111:773.</a></li><li><a class="nounderline abstract_t">Zhang S, Fang Y, Cai BW, et al. Intracystic bleomycin for cystic craniopharyngiomas in children. Cochrane Database Syst Rev 2016; 7:CD008890.</a></li><li><a class="nounderline abstract_t">Hukin J, Steinbok P, Lafay-Cousin L, et al. Intracystic bleomycin therapy for craniopharyngioma in children: the Canadian experience. Cancer 2007; 109:2124.</a></li><li><a class="nounderline abstract_t">Kilday JP, Caldarelli M, Massimi L, et al. Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN. Neuro Oncol 2017; 19:1398.</a></li><li><a class="nounderline abstract_t">Cavalheiro S, Dastoli PA, Silva NS, et al. Use of interferon alpha in intratumoral chemotherapy for cystic craniopharyngioma. Childs Nerv Syst 2005; 21:719.</a></li><li><a class="nounderline abstract_t">Cavalheiro S, Di Rocco C, Valenzuela S, et al. Craniopharyngiomas: intratumoral chemotherapy with interferon-alpha: a multicenter preliminary study with 60 cases. Neurosurg Focus 2010; 28:E12.</a></li><li><a class="nounderline abstract_t">Shi XE, Wu B, Fan T, et al. Craniopharyngioma: surgical experience of 309 cases in China. Clin Neurol Neurosurg 2008; 110:151.</a></li><li><a class="nounderline abstract_t">Elliott RE, Hsieh K, Hochm T, et al. Efficacy and safety of radical resection of primary and recurrent craniopharyngiomas in 86 children. J Neurosurg Pediatr 2010; 5:30.</a></li><li><a class="nounderline abstract_t">Stripp DC, Maity A, Janss AJ, et al. Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adults. Int J Radiat Oncol Biol Phys 2004; 58:714.</a></li><li><a class="nounderline abstract_t">Karavitaki N, Brufani C, Warner JT, et al. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf) 2005; 62:397.</a></li><li><a class="nounderline abstract_t">Lin LL, El Naqa I, Leonard JR, et al. Long-term outcome in children treated for craniopharyngioma with and without radiotherapy. J Neurosurg Pediatr 2008; 1:126.</a></li><li><a class="nounderline abstract_t">Mark RJ, Lutge WR, Shimizu KT, et al. Craniopharyngioma: treatment in the CT and MR imaging era. Radiology 1995; 197:195.</a></li><li><a class="nounderline abstract_t">Honegger J, Buchfelder M, Fahlbusch R. Surgical treatment of craniopharyngiomas: endocrinological results. J Neurosurg 1999; 90:251.</a></li><li><a class="nounderline abstract_t">Fahlbusch R, Honegger J, Paulus W, et al. Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg 1999; 90:237.</a></li><li><a class="nounderline abstract_t">Komotar RJ, Starke RM, Raper DM, et al. Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of craniopharyngiomas. World Neurosurg 2012; 77:329.</a></li><li><a class="nounderline abstract_t">Gallotti AL, Barzaghi LR, Albano L, et al. Comparison between extended transsphenoidal and transcranial surgery for craniopharyngioma: focus on hypothalamic function and obesity. Pituitary 2022; 25:74.</a></li><li><a class="nounderline abstract_t">Erfurth EM. Craniopharyngioma-An update on metabolic and cognitive complications and new therapy. J Intern Med 2023; 294:269.</a></li><li class="breakAll">Lo WB, Rutka JT. Craniopharyngioma: Complications after microsurgery. In: Complications in Neurosurgery, Nanda A (Ed), Elsevier, 2019. p.160-171.</li><li><a class="nounderline abstract_t">Olsson DS, Andersson E, Bryngelsson IL, et al. Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden. J Clin Endocrinol Metab 2015; 100:467.</a></li><li><a class="nounderline abstract_t">Lo AC, Howard AF, Nichol A, et al. Long-term outcomes and complications in patients with craniopharyngioma: the British Columbia Cancer Agency experience. Int J Radiat Oncol Biol Phys 2014; 88:1011.</a></li><li><a class="nounderline abstract_t">Edmonston DY, Wu S, Li Y, et al. Limited surgery and conformal photon radiation therapy for pediatric craniopharyngioma: long-term results from the RT1 protocol. Neuro Oncol 2022; 24:2200.</a></li><li><a class="nounderline abstract_t">Boekhoff S, Bogusz A, Sterkenburg AS, et al. Long-term Effects of Growth Hormone Replacement Therapy in Childhood-onset Craniopharyngioma: Results of the German Craniopharyngioma Registry (HIT-Endo). Eur J Endocrinol 2018; 179:331.</a></li><li><a class="nounderline abstract_t">Heinks K, Boekhoff S, Hoffmann A, et al. Quality of life and growth after childhood craniopharyngioma: results of the multinational trial KRANIOPHARYNGEOM 2007. Endocrine 2018; 59:364.</a></li><li><a class="nounderline abstract_t">Müller HL, Bruhnken G, Emser A, et al. Longitudinal study on quality of life in 102 survivors of childhood craniopharyngioma. Childs Nerv Syst 2005; 21:975.</a></li><li><a class="nounderline abstract_t">Ahmet A, Blaser S, Stephens D, et al. Weight gain in craniopharyngioma--a model for hypothalamic obesity. J Pediatr Endocrinol Metab 2006; 19:121.</a></li><li><a class="nounderline abstract_t">Hoffmann A, Bootsveld K, Gebhardt U, et al. Nonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma. Eur J Endocrinol 2015; 173:389.</a></li><li><a class="nounderline abstract_t">Fjalldal S, Holmer H, Rylander L, et al. Hypothalamic involvement predicts cognitive performance and psychosocial health in long-term survivors of childhood craniopharyngioma. J Clin Endocrinol Metab 2013; 98:3253.</a></li><li><a class="nounderline abstract_t">Özyurt J, Müller HL, Thiel CM. A systematic review of cognitive performance in patients with childhood craniopharyngioma. J Neurooncol 2015; 125:9.</a></li><li><a class="nounderline abstract_t">Dolson EP, Conklin HM, Li C, et al. Predicting behavioral problems in craniopharyngioma survivors after conformal radiation therapy. Pediatr Blood Cancer 2009; 52:860.</a></li><li><a class="nounderline abstract_t">Lo AC, Howard AF, Nichol A, et al. A Cross-Sectional Cohort Study of Cerebrovascular Disease and Late Effects After Radiation Therapy for Craniopharyngioma. Pediatr Blood Cancer 2016; 63:786.</a></li><li><a class="nounderline abstract_t">Liu AK, Bagrosky B, Fenton LZ, et al. Vascular abnormalities in pediatric craniopharyngioma patients treated with radiation therapy. Pediatr Blood Cancer 2009; 52:227.</a></li><li><a class="nounderline abstract_t">Enchev Y, Ferdinandov D, Kounin G, et al. Radiation-induced gliomas following radiotherapy for craniopharyngiomas: a case report and review of the literature. Clin Neurol Neurosurg 2009; 111:591.</a></li><li><a class="nounderline abstract_t">Wisoff JH. Surgical management of recurrent craniopharyngiomas. Pediatr Neurosurg 1994; 21 Suppl 1:108.</a></li><li><a class="nounderline abstract_t">Himes BT, Ruff MW, Van Gompel JJ, et al. Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report. J Neurosurg 2018; 130:1299.</a></li><li><a class="nounderline abstract_t">Brastianos PK, Shankar GM, Gill CM, et al. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. J Natl Cancer Inst 2016; 108.</a></li><li><a class="nounderline abstract_t">Rostami E, Witt Nyström P, Libard S, et al. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy. Acta Neurochir (Wien) 2017; 159:2217.</a></li><li><a class="nounderline abstract_t">Rodriguez FJ, Scheithauer BW, Tsunoda S, et al. The spectrum of malignancy in craniopharyngioma. Am J Surg Pathol 2007; 31:1020.</a></li><li><a class="nounderline abstract_t">Boongird A, Laothamatas J, Larbcharoensub N, Phudhichareonrat S. Malignant craniopharyngioma; case report and review of the literature. Neuropathology 2009; 29:591.</a></li><li><a class="nounderline abstract_t">Lermen O, Frank S, Hassler W. Postoperative spinal recurrence of craniopharyngioma. Acta Neurochir (Wien) 2010; 152:309.</a></li><li><a class="nounderline abstract_t">Elliott RE, Moshel YA, Wisoff JH. Surgical treatment of ectopic recurrence of craniopharyngioma. Report of 4 cases. J Neurosurg Pediatr 2009; 4:105.</a></li><li><a class="nounderline abstract_t">Frangou EM, Tynan JR, Robinson CA, et al. Metastatic craniopharyngioma: case report and literature review. Childs Nerv Syst 2009; 25:1143.</a></li><li><a class="nounderline abstract_t">Romani R, Niemelä M, Celik O, et al. Ectopic recurrence of craniopharyngioma along the surgical route: case report and literature review. Acta Neurochir (Wien) 2010; 152:297.</a></li><li><a class="nounderline abstract_t">Ravindra VM, Okcu MF, Ruggieri L, et al. Comparison of multimodal surgical and radiation treatment methods for pediatric craniopharyngioma: long-term analysis of progression-free survival and morbidity. J Neurosurg Pediatr 2021; :1.</a></li><li><a class="nounderline abstract_t">Visser J, Hukin J, Sargent M, et al. Late mortality in pediatric patients with craniopharyngioma. J Neurooncol 2010; 100:105.</a></li></ol></div><div id="topicVersionRevision">Topic 5210 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1260697" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Craniopharyngiomas: a clinical and pathological review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34608945" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9761047" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The descriptive epidemiology of craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17080265" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17630614" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Craniopharyngioma: modern concepts in pathogenesis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7960369" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : International incidence of childhood brain and spinal tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2486793" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Childhood intracranial neoplasms Enugu, Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2486793" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Childhood intracranial neoplasms Enugu, Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7373393" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Transsphenoidal microsurgery in the management of craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13471802" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Rathke-pouch tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4465421" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Third ventricle intrinsic craniopharingioma. Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5539648" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Intraventricular craniopharyngioma. Report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5539648" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Intraventricular craniopharyngioma. Report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15891929" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12466115" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24413733" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7885544" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7616262" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Papillary craniopharyngioma: a clinicopathological study of 48 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10690718" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term outcomes for surgically resected craniopharyngiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17425791" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23143722" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Headaches in children with craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31314136" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23111221" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A perspective on craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18636330" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Craniopharyngioma surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34653972" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Long-term tumor control after endoscopic endonasal resection of craniopharyngiomas: comparison of gross-total resection versus subtotal resection with radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27223498" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28434110" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29600905" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Therapeutic outcomes of transsphenoidal surgery in pediatric patients with craniopharyngiomas: a single-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37119110" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Predictors of extent of resection and recurrence following endoscopic endonasal resection of craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31222446" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Quality of life, hypothalamic obesity, and sexual function in adulthood two decades after primary gross-total resection for childhood craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30181653" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Detailed assessment of hypothalamic damage in craniopharyngioma patients with obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31699993" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21214336" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Neurosurgical treatment of craniopharyngioma in adults and children: early and long-term results in a large case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31219033" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The Postopera tive Quality of Life in Children and Adolescents with Craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20367362" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Craniopharyngioma: a comparison of tumor control with various treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18091236" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Extended endoscopic transsphenoidal approach for extrasellar craniopharyngiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29480694" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The limits of transsellar/transtuberculum surgery for craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29600903" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Editorial. Endoscopic endonasal surgery for pediatric craniopharyngiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29185147" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Predicting pituitary stalk position by in vivo visualization of the hypothalamo-hypophyseal tract in craniopharyngioma using diffusion tensor imaging tractography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23486689" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Trends in treatment and outcomes of pediatric craniopharyngioma, 1975-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23633208" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Childhood craniopharyngioma: hypothalamus-sparing surgery decreases the risk of obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37381692" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Treatment and outcome of the Dutch Childhood Craniopharyngioma Cohort study: First results after centralization of care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37437144" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37437149" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Precision Oncology for Papillary Craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19165514" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The role of fractionated radiotherapy and radiosurgery in the management of patients with craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28570730" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy of Stereotactic Conformal Radiotherapy vs Conventional Radiotherapy on Benign and Low-Grade Brain Tumors: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17469176" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Achievement of long-term local control in patients with craniopharyngiomas using high precision stereotactic radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18948720" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Long-term results of gamma knife radiosurgery for 100 consecutive cases of craniopharyngioma and a treatment strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20005637" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Radiosurgery for craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16580494" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Combined proton and photon irradiation for craniopharyngioma: long-term results of the early cohort of patients treated at Harvard Cyclotron Laboratory and Massachusetts General Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16630407" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Fractionated proton radiation treatment for pediatric craniopharyngioma: preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25052561" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36002321" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Proton therapy for adult craniopharyngioma: Experience of a single institution in 91 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1429082" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pediatric craniopharyngiomas: long term results of combined treatment with surgery and radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/615967" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Long term results in the management of craniopharyngiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1011035" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Recovery from anterograde and retrograde amnesia after percutaneous drainage of a cystic craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7350278" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Management of the unresectable cystic craniopharyngioma by aspiration through an Ommaya reservoir drainage system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3984798" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The radiotherapy of cystic craniopharyngioma with intracystic installation of 90Y silicate colloid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9007857" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cystic craniopharyngioma: long-term results after intracavitary irradiation with stereotactically applied colloidal beta-emitting radioactive sources.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7673031" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Phosphorus-32 intracavitary irradiation of cystic craniopharyngiomas: current technique and long-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1527612" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Intracavitary brachytherapy of cystic craniopharyngiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21269713" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Phosphorus-32 therapy for cystic craniopharyngiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34058257" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Evaluation of Long-Term Outcomes and Toxicity After Stereotactic Phosphorus-32-Based Intracavitary Brachytherapy in Patients With Cystic Craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27416004" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Intracystic bleomycin for cystic craniopharyngiomas in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17407137" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Intracystic bleomycin therapy for craniopharyngioma in children: the Canadian experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28499018" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16133276" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Use of interferon alpha in intratumoral chemotherapy for cystic craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20367356" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Craniopharyngiomas: intratumoral chemotherapy with interferon-alpha: a multicenter preliminary study with 60 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18063470" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Craniopharyngioma: surgical experience of 309 cases in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20043735" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Efficacy and safety of radical resection of primary and recurrent craniopharyngiomas in 86 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14967425" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15807869" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18352781" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Long-term outcome in children treated for craniopharyngioma with and without radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7568823" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Craniopharyngioma: treatment in the CT and MR imaging era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9950495" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Surgical treatment of craniopharyngiomas: endocrinological results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9950494" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Surgical treatment of craniopharyngiomas: experience with 168 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22501020" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of craniopharyngiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34236593" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Comparison between extended transsphenoidal and transcranial surgery for craniopharyngioma: focus on hypothalamic function and obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37424210" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Craniopharyngioma-An update on metabolic and cognitive complications and new therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37424210" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Craniopharyngioma-An update on metabolic and cognitive complications and new therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25375987" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24661653" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Long-term outcomes and complications in patients with craniopharyngioma: the British Columbia Cancer Agency experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35556133" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Limited surgery and conformal photon radiation therapy for pediatric craniopharyngioma: long-term results from the RT1 protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30139824" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Long-term Effects of Growth Hormone Replacement Therapy in Childhood-onset Craniopharyngioma: Results of the German Craniopharyngioma Registry (HIT-Endo).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29230635" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Quality of life and growth after childhood craniopharyngioma: results of the multinational trial KRANIOPHARYNGEOM 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16075216" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Longitudinal study on quality of life in 102 survivors of childhood craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16562584" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Weight gain in craniopharyngioma--a model for hypothalamic obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26088821" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Nonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23771923" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Hypothalamic involvement predicts cognitive performance and psychosocial health in long-term survivors of childhood craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26369768" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : A systematic review of cognitive performance in patients with childhood craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19191345" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Predicting behavioral problems in craniopharyngioma survivors after conformal radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26756999" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : A Cross-Sectional Cohort Study of Cerebrovascular Disease and Late Effects After Radiation Therapy for Craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18937328" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Vascular abnormalities in pediatric craniopharyngioma patients treated with radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19447544" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Radiation-induced gliomas following radiotherapy for craniopharyngiomas: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7841068" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Surgical management of recurrent craniopharyngiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29701552" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26498373" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28918496" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17592268" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : The spectrum of malignancy in craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19077042" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Malignant craniopharyngioma; case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19838829" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Postoperative spinal recurrence of craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19645541" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Surgical treatment of ectopic recurrence of craniopharyngioma. Report of 4 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19517118" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Metastatic craniopharyngioma: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19499168" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Ectopic recurrence of craniopharyngioma along the surgical route: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34049281" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Comparison of multimodal surgical and radiation treatment methods for pediatric craniopharyngioma: long-term analysis of progression-free survival and morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20204458" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Late mortality in pediatric patients with craniopharyngioma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
